Clinical Trial: Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Study Status: NOT_YET_RECRUITING
Recruit Status: NOT_YET_RECRUITING
Condition: Lymphoma
Study Type: INTERVENTIONAL
Official Title: Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Brief Summary:
The goal of this study is to see if the drug balstilimab is safe and effective in participants with relapsed/refractory lymphomas.Participants will receive balstilimab every 3 weeks and their outcomes will be assessed periodically.
Read more